Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 15/20 | 0.46 |
| ▸ | THRB | P10828 | 15/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359710 | 0.88 | THRA (0.56) | THRATHRBPPARGITGB3ITGAV | |
| SCHEMBL5351679 | 0.83 | THRA (0.43) | THRATHRB | |
| SCHEMBL5349027 | 0.82 | THRA (0.68) | THRATHRBPPARG | |
| SCHEMBL5858142 | 0.81 | FFAR1 (0.44) | THRATHRBPPARGRXRA | |
| SCHEMBL5355833 | 0.81 | THRB (0.55) | THRATHRB | |
| SCHEMBL12312837 | 0.80 | THRB (0.54) | THRATHRBPPARG | |
| SCHEMBL5355142 | 0.80 | THRB (0.54) | THRATHRBPPARGRXRA | |
| SCHEMBL5858330 | 0.78 | THRB (0.52) | THRATHRBPPARGRXRA | |
| SCHEMBL5355143 | 0.77 | THRA (0.52) | THRATHRBPPARG | |
| SCHEMBL5354678 | 0.76 | THRB (0.47) | THRATHRBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279593-B2 | Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | KARO BIO AB (SE) | 2007-10-09 | — | — | US | disclosed |
| US-20050107347-A1 | Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | KARO BIO AB (SE) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107347-A1 | Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | TSHR, THRB, THRA | THRA 3/4885THRB 2/4885PPARG 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.